Morgan Stanley Sage Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,594,355 shares of SAGE stock, worth $32.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,594,355

Previous 808,798 468.05%

Holding current value

$32.8 Million

Previous $5.83 Million 327.83%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.78 - $8.57 $18.1 Million - $32.4 Million	3,785,557 Added 468.05%	4,594,355 $24.9 Million
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $4.08 Million - $7.61 Million	-581,902 Reduced 41.84%	808,798 $5.83 Million
Q2 2024 Oct 17, 2024	BUY	$10.58 - $17.9 $1.42 Million - $2.4 Million	134,255 Added 10.69%	1,390,700 $15.1 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $1.42 Million - $2.4 Million	134,255 Added 10.69%	1,390,700 $15.1 Million
Q1 2024 Oct 17, 2024	SELL	$18.62 - $26.95 $2.5 Million - $3.62 Million	-134,255 Reduced 9.65%	1,256,445 $23.5 Million
Q1 2024 Aug 16, 2024	BUY	$18.62 - $26.95 $7.19 Million - $10.4 Million	385,881 Added 44.33%	1,256,445 $23.5 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $7.19 Million - $10.4 Million	385,881 Added 44.33%	1,256,445 $23.5 Million
Q4 2023 Aug 16, 2024	SELL	$17.1 - $22.26 $8.89 Million - $11.6 Million	-520,136 Reduced 37.4%	870,564 $18.9 Million
Q4 2023 Feb 13, 2024	BUY	$17.1 - $22.26 $113,407 - $147,628	6,632 Added 0.77%	870,564 $18.9 Million
Q3 2023 Nov 15, 2023	BUY	$16.75 - $48.98 $8.58 Million - $25.1 Million	512,021 Added 145.5%	863,932 $17.8 Million
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $843,121 - $1.23 Million	-20,741 Reduced 5.57%	351,911 $16.5 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $4.88 Million - $6.1 Million	-130,983 Reduced 26.01%	372,652 $15.6 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $5.25 Million - $7.1 Million	162,920 Added 47.82%	503,635 $19.2 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $7.51 Million - $10.1 Million	-232,585 Reduced 40.57%	340,715 $13.3 Million
Q2 2022 Oct 27, 2022	BUY	$27.52 - $37.99 $225,058 - $310,682	8,178 Added 1.45%	573,300 $18.5 Million
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $225,058 - $310,682	8,178 Added 1.45%	573,300 $18.5 Million
Q1 2022 Oct 27, 2022	SELL	$30.71 - $45.71 $251,146 - $373,816	-8,178 Reduced 1.43%	565,122 $18.7 Million
Q1 2022 May 13, 2022	BUY	$30.71 - $45.71 $8.49 Million - $12.6 Million	276,594 Added 95.86%	565,122 $18.7 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $1.72 Million - $2.18 Million	-46,312 Reduced 13.83%	288,528 $12.3 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $13.5 Million - $19.2 Million	334,840 New	334,840 $14.8 Million

Others Institutions Holding SAGE

# of Institutions

193

Shares Held

45M

Call Options Held

304K

Put Options Held

117K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $424M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account